NASDAQ$SEER
Seer Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Seer reported Q1 2026 revenue of $2.8M with a net loss of $16.8M and diluted loss per share of $0.30.
For the quarter ended March 31, 2026, Seer recognized revenue of $2.8 million, down from $4.0 million, primarily from Proteograph platform product and service sales. Net loss was $16.8 million versus $18.8 million a year ago, with diluted loss per share of $0.30 compared with $0.34. R&D expense was $9.8 million and SG&A $8.9 million as the proteomics company continued commercial and development activities.
- Revenue of $2.8M from Proteograph products and services.
- Net loss improved to $16.8M; diluted EPS was a loss of $0.30.
- R&D spend of $9.8M supports platform and assay development.
- Commercial adoption of proteomics workflows remains the growth lever.
- Operating cash burn moderated versus prior-year quarter.
Headline financials
Revenue & EPS history
Seer · Revenue · Quarterly
$2.79M
Revenue by segment
Seer · $3.81M total across 3 segments · Q3 2023
- Product Revenue$1.85M-28.1%48.5%
- Related Party Revenue$1.43M+8.6%37.5%
- Service Revenue$536K-21.8%14.1%
Forward guidance
Seer does not issue quantitative annual guidance in the 10-Q and discusses Proteograph placements, consumable pull-through, and partnership opportunities in MD&A.
Tailwinds
- Lower net loss and improved loss per share versus Q1 2025.
- Platform revenue provides early commercial traction.
Headwinds
- Revenue declined year over year on lower product/service volume.
- Continued R&D and SG&A spend keep the company loss-making.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-1.1%
Avg return
Earnings day
-3.4%
Avg return
5 days after
-1.5%
Avg return
30 days after
38%
9 / 24 earnings
Positive
+39.4%
Q4 2022
Best reaction
-33.3%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.7% | -7.7% | -6.0% | |
| Q4 2025 | -17.4% | -11.1% | -20.2% | |
| Q3 2025 | -1.4% | -4.6% | -13.4% | |
| Q1 2025 | +10.0% | +7.8% | +7.8% | |
| Q4 2024 | -4.5% | -7.3% | -20.9% | |
| Q3 2024 | +9.4% | +10.3% | +22.2% | |
| Q2 2024 | +0.0% | -1.2% | -4.7% | |
| Q1 2024 | -6.8% | -10.0% | -21.7% | |
| Q4 2023 | +1.1% | +6.1% | +5.6% | |
| Q3 2023 | -7.4% | -11.4% | -5.1% | |
| Q2 2023 | -33.3% | -40.6% | -43.6% | |
| Q1 2023 | -2.2% | -11.2% | +33.7% | |
| Q4 2022 | +39.4% | +20.8% | -1.3% | |
| Q3 2022 | -3.4% | +22.0% | -7.4% | |
| Q2 2022 | +19.5% | +6.9% | -12.4% | |
| Q1 2022 | +5.5% | -5.7% | +5.7% | |
| Q4 2021 | -6.6% | -15.3% | +1.8% | |
| Q3 2021 | -11.4% | -13.5% | -31.0% | |
| Q3 2020 | -11.4% | -13.5% | -31.0% | |
| Q2 2021 | +8.1% | -0.8% | +44.5% | |
| Q2 2020 | +8.1% | -0.8% | +44.5% | |
| Q1 2020 | -11.4% | -8.8% | +4.1% | |
| Q1 2021 | -16.1% | -22.2% | -17.9% | |
| Q4 2020 | +7.6% | +29.9% | +31.1% | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro